28.10.2016
SHOP APOTHEKE EUROPE N.V. NL0012044747
DGAP-News: SHOP APOTHEKE EUROPE N.V.: Exercise of greenshoe option and early termination of stabilisation period
DGAP-News: SHOP APOTHEKE EUROPE N.V. / Key word(s): IPO/Banking Syndicate
SHOP APOTHEKE EUROPE N.V.: Exercise of greenshoe option and early
termination of stabilisation period
28.10.2016 / 18:27
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OF
AMERICA, CANADA, AUSTRALIA OR JAPAN. -
SHOP APOTHEKE EUROPE N.V.: Exercise of greenshoe option and early
termination of stabilisation period
Venlo/Cologne, 28 October 2016. SHOP APOTHEKE EUROPE N.V. ("SHOP APOTHEKE
EUROPE" or the "Company") has been informed by Berenberg as stabilisation
manager of the Initial Public Offering ("IPO") that Berenberg today almost
fully exercised the greenshoe option relating to up to 535,714 shares,
which was granted to the syndicate banks in connection with the IPO, in the
volume of 532,019 shares. Upon exercise of the greenshoe option, which was
provided by a group of existing shareholders, the free float remains at c.
49% and the stabilisation period is terminated early.
Michael Köhler, CEO of SHOP APOTHEKE EUROPE: "We are very satisfied with
the first trading price, which was set at EUR 30.05, and the first two
weeks of trading in the stock. The early and almost full exercise of the
greenshoe option complements the successful IPO. The stable share
performance reflects the long-term interest of our shareholders in the
future development of SHOP APOTHEKE EUROPE."
Berenberg and Citigroup acted as Joint Global Coordinators and, together
with Commerzbank, as Joint Bookrunners in connection with the IPO. Lilja &
Co. served as independent advisor to the management and the owners of SHOP
APOTHEKE EUROPE. Parklane Capital acted as Financial Advisor to the
shareholders of SHOP APOTHEKE EUROPE.
About SHOP APOTHEKE EUROPE
SHOP APOTHEKE EUROPE is one of Continental Europe's leading online
pharmacies with a portfolio that focuses on OTC medication and pharmacy-
related BPC products. The Company operates online pharmacies in Germany,
Austria, France, Belgium, Italy, Spain and the Netherlands. In Germany,
TÜV-certified shop-apotheke.com is the market leader in terms of traffic,
delivering a broad range of approximately 100,000 original products to
about 1.5 million active customers quickly and at a good price. In
addition, SHOP APOTHEKE EUROPE provides comprehensive and consistent
pharmaceutical services.
SHOP APOTHEKE EUROPE generated over EUR 125 million in revenues in the
financial year 2015. Headquartered in Venlo (Netherlands), SHOP APOTHEKE
EUROPE also has an administration site for its sales and marketing units in
Cologne (Germany).
MEDIA CONTACTS
Trade and public media:
Sven Schirmer
Mobile: +49 152 28 50 63 61
Email: [email protected]
Financial media:
Bettina Fries
Mobile: +49 172 297 62 43
Email: [email protected]
Disclaimer
This announcement does not, and shall not, in any circumstances constitute
a public offering, nor an offer to subscribe any securities in any
jurisdiction. The offering was made only on the basis of the securities
prospectus issued by the Company in connection with the offering. The
shares have already been sold.
This communication is not for publication or distribution, directly or
indirectly, in or into the United States, Canada, Australia or Japan. This
communication does not constitute or form part of an offer of securities
for sale or solicitation of an offer to purchase securities in the United
States, Canada, Australia, Japan or in any other jurisdiction in which such
offer may be restricted. The securities referred to in this communication
have not been, and will not be, registered under the US Securities Act of
1933, as amended (the "Securities Act"), and may not be offered or sold in
the United States, except on the basis of an applicable exemption from the
registration requirements or in a transaction not subject to the
registration requirements of the Securities Act. There will be no public
offering of securities in the United States.
In the United Kingdom, this communication is directed only at persons who:
(i) are qualified investors within the meaning of the Financial Services
and Markets Act 2000 (as amended) and any relevant implementing measures
and/or (ii) are outside the United Kingdom or (iii) have professional
experience in matters relating to investments and fall within the
definition of "investment professionals" contained in article 19(5) of the
Financial Services and Markets Act 2000 (Financial Promotion) Order 2005
(as amended) (the "Order") or are persons falling within article 49(2)(a)
to (d) (high net worth companies, unincorporated associations, etc.) of the
Order, or fall within another exemption to the Order (all such persons
referred to in (i) to (iii) above together being referred to as "Relevant
Persons"). Any person who is not a Relevant Person must not act or rely on
this communication or any of its contents. Any investment or investment
activity to which this communication relates is available only to Relevant
Persons and will be engaged in only with Relevant Persons.
This communication contains statements related to future business and
financial performance and future events or developments involving SHOP
APOTHEKE EUROPE that may constitute forward-looking statements.
These statements may be identified by words such as "expect", "intend",
"look forward to", "believe", "will" or other words of similar meaning.
Such statements are based on current expectations and certain assumptions
of SHOP APOTHEKE EUROPE's management, of which many are out of our control.
These are subjects to a number of risks and uncertainties. Should one or
more of this risks or uncertainties materialize, or should underlying
expectations not occur or assumptions prove incorrect, actual results,
performance or achievements of SHOP APOTHEKE EUROPE may (negatively or
positively) vary materially from those described explicitly or implicitly
in the relevant forward-looking statement. SHOP APOTHEKE EUROPE does not
intend or assume any obligation to update or revise these forward-looking
statements in light of developments which differ from those anticipated.
---------------------------------------------------------------------------
28.10.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: SHOP APOTHEKE EUROPE N.V.
Dirk Hartogweg 14
5928 LV Venlo
Netherlands
Phone: 0800 - 200 800 300
Fax: 0800 - 90 70 90 20
E-mail: [email protected]
Internet: www.shop-apotheke-europe.com
ISIN: NL0012044747
WKN: A2AR94
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
515781 28.10.2016
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
SHOP APOTHEKE EUROPE N.V. ISIN: NL0012044747 können Sie bei EQS abrufen
E-Commerce , A2AR94 , RDC , XETR:SAE